Summary
Background/objectives: Uracil and tegafur in a 4:1 molar concentration ratio (UFT; Bristol-Myers Squibb, Wallingford, CT) has broad anti-tumor activity for cancers arising from the gastrointestinal tract. However, there are no published data regarding the efficacy of leucovorin-modulated UFT in patients with pancreatic cancer. The objective of this trial was to determine the activity and evaluate the toxicity of UFT plus oral calcium leucovorin in patients with advanced pancreatic adenocarcinoma.
Patients and methods: Fourteen patients with advanced measurable adenocarcinoma of the pancreas were enrolled onto the trial. Patients received 300 mg/m 2 /d UFT plus 90 mg/d leucovorin administered orally in divided doses every eight hours for 28 days repeated every 35 days. Objective tumor response was evaluated after two courses of therapy.
Results: Fourteen patients were evaluable for response and toxicity. No objective responses were seen. The median (range) time to progression and survival were 14 (1.6-37), and 15 (1.9-62) weeks, respectively. Toxicity was mild with severe (grade 3 or 4) hyperbilirubinemia, pain, diarrhea, transaminitis, venous thrombus, weakness, renal failure, confusion, and edema/ascites seen in three (21%), one (7%), two (14%), one (7%), one (7%), one (7%), one (7%), one (7%), and two (14%) patients, respectively.
Conclusion: In the 14 patients evaluable, UFT 300 mg/m 2 /d plus oral leucovorin 90 mg/d administered for 28 days did not demonstrate anti-tumor activity against advanced pancreatic adenocarcinoma; however, this oral regimen was well tolerated and devoid of neutropenia, significant oral mucositis or diarrhea.
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Introduction
Advanced, surgically unresectable pancreatic cancers are incurable. Most patients die of disease progression within a year of diagnosis. The impact of systemic therapy on the prognosis of this disease has been negligible and even gemcitabine yields only an 11% objective response rate with a median survival of 5.7 months [1] . Fluorouracil (5-FU) has been studied most extensively using a variety of doses and schedules, but the response rate widely varies between 5%-30% and no consistent effect on disease-related symptoms or survival has been demonstrated [2] .
UFT is an orally administered drug which is a combination of l-(2-tetrahydrofuryl)-5-fluorouracil (tegafur) with uracil in a 1:4 molar ratio [3] . Tegafur is converted by liver microsomes to 5-fluorouracil (5-FU) which then is either phosphorylated to active nucleotide derivatives or degraded. The degradation to inactive metabolites is inhibited by uracil resulting in augmented 5-FU antitumor activity. 5-FU concentrations in tumor tissue following oral administration of tegafur are two to 10 times higher than those in blood providing some tumor selectivity of the drug [5] [6] [7] [8] . Leucovorin (LV) has the potential of modulating UFT activity [4] . Phase I and II trials with UFT have been conducted mainly in Japan and anti-tumor activity has been demonstrated in a variety of malignancies including colorectal, breast, cervical, genitourinary and head and neck cancer. In one pancreatic cancer trial, UFT alone at doses between 400-600 mg/day produced an overall response rate of 17.4% in 23 evaluable patients [4] [5] [6] [7] [8] . This study is the first to report on the use of UFT and leucovorin in advanced pancreatic cancer [9] .
Patients and methods
Fourteen patients with advanced unresectable pancreatic adenocarcinoma were entered onto the trial through a phase II Cooperative Agreement Network based at the University of Chicago [9] , between August 5, 1996 and September 30, 1997. Eligibility included histologically confirmed diagnosis of adenocarcinoma of the pancreas, measurable disease in two dimensions as defined by CT scan, Karnofsky performance status ^60%, and adequate organ function defined as absolute neutrophil count (ANC) > 1500/ul, platelets >100,000/ul, serum creatinine <2.0 mg/dl, total bilirubin ^1.5 mg/dl, transaminases $ 2.5x upper limit of institutional normal, and serum albumin 2.5 mg/dl. Patients who had prior chemotherapy for advanced or metastatic disease were excluded. Written informed consent was obtained from all patients prior to study entry.
UFT was administered orally at a dose of 300 mg/m 2 /day and leucovorin at 90 mg/day with both drugs given in three divided doses daily for 28 days repeated every 35 days. Patients were advised to take 5 to 10 oz of water with the medications and not to consume any food or juice one hour before and after ingestion of the medications. A course of therapy was defined as 28 consecutive days of treatment followed by a seven-day rest period.
Treatment with loperamide (Janssen Pharmaceutica, Inc, Piscataway, NJ) was initiated for diarrhea > grade 2. Blood counts were obtained weekly, physical examinations and symptom assessments were done every five weeks and CT scans performed every 10 weeks. Patients were treated until the appearance of disease progression using standard criteria for objective response assessment.
For absolute neutrophil count (ANC) < 1000/uI and platelets =£50,000/ul, dosing was delayed until recovery of ANC and platelets to > 1500/ul and 150,000/ul, respectively. For nonhematologic toxicity, dosing was delayed for NCI common toxicity criteria grade 2 or greater and resumed when this subsided to grade 1 or less. Retreatment criteria were identical; however, for previous grade 3-4 toxicity, retreatment was initiated at UFT doses reduced by 50 mg/m 2 . Dose escalation was not allowed. Leucovorin doses were not modified.
After two courses of treatment, response was evaluated by CTscan. Using an intent to treat principle, we considered all patients evaluable for response as having completed atleast one dose of the study drugs. Time to disease progression was determined as the time interval from first treatment day until objective progression determined by CT scan or clinical progression determined by physical examination and or toxicity necessitating discontinuation of protocol treatment. Overall survival was determined as the time interval from the first treatment day until death.
Results
Fourteen patients were entered on this study. Patient characteristics included nine females and five males, median age 69 years, 13 patients had performance status 0-1, one patient had adjuvant radiotherapy and all patients had metastatic disease within the abdomen. A total of 26 courses of treatment were administered (median 1, range 1-4). Seven patients received only a single course of treatment because of disease progression. Of the remaining seven patients who received two or more chemotherapy cycles, no patients required dose modification for hematologic toxicity; however, one patient was dose reduced for non-hematologic toxicity (grade 3 hyperbilirubinemia and grade 2 fever). No objective responses were seen. Three patients had stable disease lasting 10 to 34+ weeks while three patients experienced rapid disease progression. One patient went off-study after cycle 1 due to toxicity resulting in a prolonged dosing delay. Of the three patients with stable disease, two patients had disease progression documented within four weeks prior to study entry and the third patient was (28) 6(42) 5(35) 4(28) 1(7) 1 (7) 0(0) 1(7) 2(14) 1 (7) 0(0) 1(7) 0(0) 1(7) 0(0) 1(7) 0(0) 1(7) 0(0) 2 (%) 1 (7) 2(14) 5(35) 3(21) 2(14) 3 (21) 6(42) 0(0) 0(0) 0(0) 0(0) 0(0) 2(14) 0(0) 4(28) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 3 (%) 0(0) 0(0) 0(0) 1 (7) 0(0) 1(7) 0(0) 1(7) 1 (7) 0(1) 0(0) 0(0) 2(14) 1 (7) 1 (7) 0(0) 1(7) 0(0) 0(0) 0(0) 1(7) 4(%) 0(0) 1 (7) 0(0) 0(0) 0(0) 1(7) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 1(7) 0(0) 0(0) 0(0) 0(0) 0(0) 1(7) 0(0) 0(0) initially diagnosed with metastatic pancreatic cancer 18 days prior to receiving treatment. The median (range) time to progression and overall survival were 13.6 (1.6-37), and 14.9 (1.9-62) weeks, respectively. All 14 patients were evaluable for toxicity and all toxicity grades have been listed in Table 1 . One patient expired during the first cycle of treatment (day 37) as a result of deep vein thrombosis leading to a pulmonary embolus. This patient had grade 3 confusion and weakness (day 24) and lower extremity edema (day 1-2). Another patient expired during cycle 1 day 21 secondary to profound dehydration and pre-renal azotemia resulting from grade 3 protracted vomiting. There were three episodes of grade 3-4 hyperbilirubinemia on treatment. Two patients had normalization of bilirubin levels to baseline after cessation of UFT/leucovorin. One patient developed grade 3 transaminitis on cycle 1 day 7 and, despite discontinuation of UFT, developed irreversible hyperbilirubinemia on day 29 which was thought to be due to disease progression within the liver. Other grade 1-2 toxic reactions included fever, pain, anorexia, nausea, vomiting, diarrhea, fatigue, rash, stomatitis, asthenia, and dysgeusia. Diarrhea (seven episodes of grade 1-2) was an uncommon side-effect in our population of patients and typically responded to dosing delays. No significant neutropenia (median nadir granulocyte count, 3625/ul, range 1820 to 9222/ul), thrombocytopenia, acral erythema (hand-foot syndrome), or oral mucositis were observed. In a prior study (n = 45) excessive lacrimation, photosensitivity and mild maculopapular skin rashes have been observed with administration of this combination [13] ; however, in our limited pancreatic cancer population, only two patients reported mild grade 1 rash which responded to topical treatment. In patients receiving multiple courses of UFT with leucovorin (n = 7), no patient experienced cumulative toxicity.
Of the 26 courses of UFT administered, eight courses (seven patients) had interruptions of two to five days and only four courses (three patients) of therapy were interrupted for longer than seven days.
families for their support of this project. We thank the housestaff, postdoctoral fellows, and attending physicians who cared for their patients and Deborah Stoit who provided expert secretarial assistance. Finally, we thank L. Ph. Schumm (Department of Health Studies, University of Chicago, Chicago, IL) for performing the statistical calculations in this paper.
Discussion
The lack of any objective responders in this study (90% upper confidence bound of 16%) indicates that UFT in combination with LV given in this schedule is inactive in advanced previously untreated pancreatic cancer. Although this trial is powered to detect a response ratê 20%, it is conceivable that we are missing a true response rate of 5%-15% which would be deletable if the sample size were larger. However, a response rate < 20% would not be clinically meaningful especially in the context of a of a wide confidence interval and other agents like 5-FU that give similar response rates. The earlier studies conducted in Japan initially described anecdotal reports of pancreatic tumor regression after treatment with up to 600 mg/day of UFT without leucovorin [10, 11] . In a Japanese retrospective analysis, results of pancreatic cancer patients treated with UFT at doses between 400 to 600 mg/m 2 /day revealed significantly better overall survival than those who had not received UFT (P -0.009) [12] . From a nationwide pooled data base, Ota et al report that at these doses there was an overall response rate of 17.4% in patients with pancreatic cancer [8] . Our results, despite using an LV-modulated schedule, do not confirm these observations. It is conceivable, however, that with the addition of leucovorin, the UFT dose intensity may have been reduced to sub-therapeutic levels resulting in an inactive regimen.
Overall, the level of toxicity observed in this study suggest that the regimen is well tolerated.
UFT 300 mg/m 2 /d plus oral leucovorin 90 mg/d administered for 28 days did not, however, demonstrate objective anti-tumor activity against advanced pancreatic adenocarcinoma in 14 patients so far evaluated.
